Daniel Guay

Daniel is a seasoned leader in drug discovery with over 35 years of experience in the industry and a strong focus on medicinal chemistry. Daniel has played a key role in advancing multiple drug candidates into clinical development, working in both large pharma (Merck) and CROs. He currently serves as Senior Executive Vice President, Corporate and Scientific Affairs at Sygnature Discovery in North America following the acquisition of Canada-based CRO NuChem Sciences, which he co-founded in 2011. 

Daniel holds a PhD in Organic Chemistry from the University of Sherbrooke and completed a postdoctoral fellowship at Stanford University.